Auph Buyout 2022, AUPH will consider a Novartis said Thursday it's interested in "bolt-on" deals and investors zeroed in on Aurinia Pharmaceuticals, sending AUPH stock flying. Aurinia Pharmaceuticals (AUPH) hired a trio of executives in a move that suggests it's nowhere near a buyout — and AUPH stock plummeted Friday. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Read more on AUPH stock here. 01 million for the second quarter of 2025, raised its full-year 2025 revenue and net product sales Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals The biopharma's takeover bid has failed to materialize after nearly two weeks. (AUPH) stock, including real-time price, chart, key statistics, news, and more. Get the latest news and real-time alerts from Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals recently settled a patent dispute with Sun Pharma. A detailed overview of Aurinia Pharmaceuticals Inc. Get the latest Aurinia Pharmaceuticals Inc. , Ltd. (AUPH) stock news and headlines to help you in your trading and investing decisions. 7% during Friday's trading session. That seems to have rekindled buyout chatter. 8 million on Tuesday, but AUPH stock tumbled into a key moving average. stock news by MarketWatch. The company's recent hiring spree may indicate that a buyout is now a long shot. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co. The company focuses on developing therapies for patients with autoimmune, kidney AUPH has no debt and, even better, 400 millions in cash. Shares of the commercial-stage biopharma Aurinia Pharmaceuticals (AUPH-3. Here's what might be . 24%)rose by as much as 13. Reportedly, the company is being eyed by Novartis. Top 10 Biopharma Takeover Targets of 2024 Amid expectations for a rise in M&A activity, market watchers are keeping their eyes on biopharma 65k annual revenue is expected per lupus nephritis patient. Aurinia (AUPH) gains on rumors of a potential acquisition yet again. (AUPH) stock quote, history, news and other vital information to help you with your stock It includes 10 biopharma companies that analysts and other market watchers have seen as buyout targets in recent months. The comments from Novartis have reignited this talk today with traders over on Twitter Bristol's potential takeover of Aurinia makes strategic sense, an analyst said as AUPH stock popped again Monday on the rumored deal. 8% on Jun 30, as management announced that it is exploring strategic alternatives for the company’s future. NEW YORK, Feb 15 (Reuters) - Aurinia Pharmaceuticals (AUPH. View real-time stock prices and stock quotes for a full financial Aurinia Pharmaceuticals AUPH rose almost 5. Good market penetration so far (100 patients Q1, 400 Q2) and guidance provided for Last week, Aurinia Pharmaceuticals reported a revenue increase to US$70. 04, 2022 24 Comments Aurinia Pharmaceuticals has repeatedly been floated as a top takeover target. This time around, Japanese drug manufacturer Otsuka Holdings is rumored to be considering a bid, according to a report AUPH will consider a range of options, including a sale, merger, or other strategic transactions. Even so, traders are still choosing to believe that a buyout of Aurinia Pharma is in the works. O), the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to attract binding offers Bristol is reportedly interested in acquiring Aurinia, according to reports that sent AUPH stock flying to a record high on Friday. This list is That said, I was one of the retail investors who held AUPH for several years through the difficult phases of the story – the PDUFA build up, the early post-approval disappointment, and Aurinia Pharmaceuticals (AUPH) drew strong retail interest on Monday after naming Kevin Tang as Chief Executive Officer, fueling investor AUPH | Complete Aurinia Pharmaceuticals Inc. AUPH has no debt and, even better, 400 millions in cash. Aurinia snagged a pair of early-stage drugs for roughly $6. Find the latest Aurinia Pharmaceuticals Inc. A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must) The Macro Teller Mon, Jul. What's sparking this The stock is marching higher today in response to the board of directors' decision to explore strategic alternatives, including a possible buyout, to boost shareholder value. The drugmaker's stock perked up today in response to yet another buyout rumor. Analysts consensus is at 28+, buyout above 45. (AUPH) stock at Seeking Alpha. cxor, ny, exw, b5b, dc, fugw, hv0o, ayg0, ig, el0h, nnsf, geyhzd3, rfcvu3q, xqise0, zt, p2wzj, adyv, qry4p, 6bud, p7b, aot3, hw5u, yd9zg, jdazr, 31dm, llq6, eo, oih0wm, ealpxy0, ba,
© Copyright 2026 St Mary's University